Physician profile
Amy North
NPI 1699189332
$2,819.12
in general payments reported to CMS, 2019-2025
33 companies · $784 in 2025
The $784 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $264 · 2021: $133 · 2022: $665 · 2023: $583 · 2024: $390 · 2025: $784.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,758.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,757.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $459.62 | 2021-2025 | |
| Amgen INC. | $313.95 | 2019-2025 | Otezla, Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $275.15 | 2019-2025 | Ofev, Jardiance |
| Astrazeneca Pharmaceuticals LP | $216.29 | 2019-2025 | Airsupra, Farxiga |
| Lundbeck LLC | $186.32 | 2024-2025 | Rexulti |
| Lilly USA, LLC | $136.04 | 2019-2025 | Mounjaro, Jardiance, Kisunla |
| Novo Nordisk INC | $127.29 | 2022-2023 | Rybelsus, Ozempic, Saxenda |
| Pfizer INC. | $124.64 | 2019-2024 | |
| Astellas Pharma US INC | $118.08 | 2023-2025 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $102.77 | 2025 | Caplyta |
| Sanofi-Aventis U.S. LLC | $96.98 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $78.59 | 2023-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Dexcom, INC. | $69.58 | 2024-2025 | Dexcom G6 Transmitter |
| Vanda Pharmaceuticals INC. | $60.44 | 2025 | Fanapt |
| Kowa Pharmaceuticals America, INC. | $44.56 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $41.86 | 2019-2024 | Invega Sustenna |
| Novartis Pharmaceuticals Corporation | $36.51 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $33.32 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $31.63 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $29.67 | 2019-2025 | Cobenfy |
| Takeda Pharmaceuticals U.S.A., INC. | $26.05 | 2022 | |
| Boston Scientific Corporation | $22.42 | 2023 | Watchman Flx |
| Mylan Specialty L.P. | $21.82 | 2023 | Yupelri |
| Viatris Specialty LLC | $21.17 | 2025 | Yupelri |
| Merck Sharp & Dohme LLC | $20.22 | 2024 | Gardasil 9, Gardasil, M-M-R II |
| Sumitomo Pharma America, INC. | $19.62 | 2023 | Gemtesa |
| Paratek Pharmaceuticals, INC. | $18.10 | 2023 | Nuzyra |
| Exact Sciences Corporation | $16.68 | 2023 | Cologuard Collection Kit |
| Vertex Pharmaceuticals Incorporated | $16.49 | 2025 | |
| Allergan, INC. | $15.31 | 2019 | |
| Organon LLC | $13.80 | 2023 | Nexplanon |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.53 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $11.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy North listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.